tetano
Editor, Senior Moderator
Viruses
. 2020 Jun 29;12(7):E703.
doi: 10.3390/v12070703.
Combinatory Treatment With Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection
Sebastian Schloer[SUP] 1 [/SUP], Jonas Goretzko[SUP] 1 [/SUP], Stephan Pleschka[SUP] 2 [/SUP], Stephan Ludwig[SUP] 3 [/SUP], Ursula Rescher[SUP] 1 [/SUP]
Affiliations
Abstract
Influenza virus infections and their associated morbidity and mortality are a major threat to global health. Vaccination is an effective influenza prevention measure; however, the effectiveness is challenged by the rapid changes in the influenza virus genome leading to viral adaptation. Emerging viral resistance to the neuraminidase inhibitor oseltamivir limits the treatment of acute influenza infections. Targeting influenza virus‑host interactions is a new and emerging field, and therapies based on the combination of virus‑ and host‑directed drugs might significantly improve treatment success. We therefore assessed the combined treatment with oseltamivir and the repurposed antifungal drug itraconazole on infection of polarized broncho‑epithelial Calu-3 cells with pdm09 or Panama influenza A virus strains. We detected significantly stronger antiviral activities in the combined treatment compared to monotherapy with oseltamivir, permitting lower concentrations of the drug than required for the single treatments. Bliss independence drug interaction analysis indicated that both drugs acted independently of each other. The additional antiviral effect of itraconazole might safeguard patients infected with influenza virus strains with heightened oseltamivir resistance.
Keywords: additivity; combination therapy; drug repurposing; host‑directed therapy; influenza A virus; itraconazole; oseltamivir.
. 2020 Jun 29;12(7):E703.
doi: 10.3390/v12070703.
Combinatory Treatment With Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection
Sebastian Schloer[SUP] 1 [/SUP], Jonas Goretzko[SUP] 1 [/SUP], Stephan Pleschka[SUP] 2 [/SUP], Stephan Ludwig[SUP] 3 [/SUP], Ursula Rescher[SUP] 1 [/SUP]
Affiliations
- PMID: 32610711
- DOI: 10.3390/v12070703
Abstract
Influenza virus infections and their associated morbidity and mortality are a major threat to global health. Vaccination is an effective influenza prevention measure; however, the effectiveness is challenged by the rapid changes in the influenza virus genome leading to viral adaptation. Emerging viral resistance to the neuraminidase inhibitor oseltamivir limits the treatment of acute influenza infections. Targeting influenza virus‑host interactions is a new and emerging field, and therapies based on the combination of virus‑ and host‑directed drugs might significantly improve treatment success. We therefore assessed the combined treatment with oseltamivir and the repurposed antifungal drug itraconazole on infection of polarized broncho‑epithelial Calu-3 cells with pdm09 or Panama influenza A virus strains. We detected significantly stronger antiviral activities in the combined treatment compared to monotherapy with oseltamivir, permitting lower concentrations of the drug than required for the single treatments. Bliss independence drug interaction analysis indicated that both drugs acted independently of each other. The additional antiviral effect of itraconazole might safeguard patients infected with influenza virus strains with heightened oseltamivir resistance.
Keywords: additivity; combination therapy; drug repurposing; host‑directed therapy; influenza A virus; itraconazole; oseltamivir.